Información sobre riesgo, prevención, detección, síntomas, diagnosis, tratamiento y apoyo para el cáncer.
Información sobre el tratamiento del cáncer incluyendo quirúrgica, quimioterapia, radioterapia, estudios clínicos, terapia con protón, medicina complementaria avanzadas.
OncoLink se complace en ofrecer una amplia lista de lista completa de los agentes quimioterapéuticos más comúnmente usados??. Esta guía de referencia incluye información sobre la forma en que cada fármaco se administra, cómo funcionan, y los pacientes los efectos secundarios comunes pueden experimentar.
Maneras que los pacientes de cáncer y las personas que le cuidan puedan enfrentar el cáncer, los efectos secundarios, nutrición, cuestiones en general sobre el apoyo para el cáncer, duelo/decisiones sobre el termino de vida, y experiencias compartidas por sobrevivientes.
Profesionales de la salud / / / /
|
10 Year Follow-Up of RTOG 92-02: A Phase III Trial of the Duration of Elective Androgen Deprivation in Locally Advanced Prostate Cancer
Presenter: G. HanksPresenter's Affiliation: Fox Chase Cancer CenterType of Session: ScientificBackground Multiple large randomized trials have demonstrated a clinical benefit with the addition of androgen deprivation to external beam... |
|
|
Analysis of V20 and Radiation Pneumonitis on SWOG 0023: A Phase III Trial of Concurrent Chemoradiation and Docetaxel Consolidation in Stage III Non-small Cell Lung Cancer
Presenter: L.E. Gaspar Presenter's Affiliation: University of Colorado at Denver Health Sciences Center Type of Session: Scientific Background SWOG 0023 was a prospective, randomized, multi-institutional phase III trial evaluating the use of... |
|
|
Analysis of V20 and Radiation Pneumonitis on SWOG 0023: A Phase III Trial of Concurrent Chemoradiation and Docetaxel Consolidation in Stage III Non-small Cell Lung Cancer
Analysis of V20 and Radiation Pneumonitis on SWOG 0023: A Phase III Trial of Concurrent Chemoradiation and Docetaxel Consolidation in Stage III Non-small Cell Lung Cancer SWOG 0023 was a phase III trial evaluating the use of radiation therapy given... |
|
|
Analyzing Serial Hypoxia Images from 18 FMISO-PET: Modeling Transient and Chronic Hypoxia
Presenter: Kelin Wang, PhDPresenter's Affiliation: Memorial Sloan-Kettering, New York, NYType of Session: PlenaryBackground Oxygen is an important mediator of radiation-induced DNA damage. Thus, tumor hypoxia impedes the ability of radiation to... |
|
|
Biochemical Recurrence and Late Toxicity Following External Beam Radiotherapy Combined With Permanent Source Prostate Brachytherapy: Analysis of RTOG 0019
Presenter: W. LeePresenter's Affiliation: Wake Forest University School of MedicineType of Session: ScientificBackground Previous clinical trials have shown the benefits of dose escalation with external beam radiation for patients with prostate... |
|
|
Biochemical Recurrence and Late Toxicity Following External Beam Radiotherapy Combined With Permanent Source Prostate Brachytherapy: Analysis of RTOG 0019
Biochemical Recurrence and Late Toxicity Following External Beam Radiotherapy Combined With Permanent Source Prostate Brachytherapy: Analysis of RTOG 0019 Previous clinical trials have demonstrated the benefits of higher doses of external beam... |
|
|
Patterns of Failure Following the Brachytherapy Management of Prostate Cancer
Presenter: R.G. StockPresenter's Affiliation: Mount Sinai Medial Center, New York, NYType of Session: ScientificBackground There are relatively few studies with long-term outcomes for men who have been treated with radioactive seed implant... |
|
|
Patterns of Failure Following the Brachytherapy Management of Prostate Cancer
Patterns of Failure Following the Brachytherapy Management of Prostate Cancer There are relatively few studies with long-term outcomes for men who have been treated with radioactive seed implant (brachytherapy) for prostate cancer. It is important... |
|
|
Quantitative Characterization of Radiation Dose Dependent Changes in Normal- Appearing White Matter of Cerebral Tumor Patients Using Diffusion Tensor Imaging
Presenter: V. NageshPresenter's Affiliation: University of Michigan, Ann Arbor, MIType of Session: PlenaryBackground Radiation effects on normal brain tissue can include neuroinflammation, demyelination, disruption of the blood-brain barrier,... |
|
|
The Prediction of Radiation-Induced Liver Dysfunction Using a Local Dose and Regional Venous Perfusion Model
Presenter: Y. CaoPresenter's Affiliation: University of Michigan, Ann Arbor, MIType of Session: PlenaryBackground High-dose conformal radiation therapy with chemotherapy can prolong the survival of patients with unresectable liver tumors. ... |
Dr. Mao talks about complementary and alternative medicine and the importance of being open about their use with cancer caregivers. Read more.
Cancer Types
Bone Cancer
Brain Tumors
Breast Cancer
Carcinoid Tumors
Endocrine System Cancers
Gastrointestinal Cancers
Gynecologic Cancers
Head and Neck Cancers
Leukemia
Lung Cancers
Lymphomas
Myelomas
Pediatric Cancers
Penile Cancer
Prostate Cancer
Sarcomas
Skin Cancers
Testicular Cancer
Thyroid Cancer
Urinary Tract Cancers
OncoLink Vet
Cancer Treatment
Biologic Therapy
Bone Marrow Transplants
Chemotherapy
Clinical Trials
Complementary Medicine
Gene Therapy
General Treatment Concerns
Hormone Therapy
PDT Center
Proton Therapy
Radiation Oncology
Surgical Oncology
Targeted Therapies
Vaccine Therapies
Cancer Support
Caregivers
Hospice Care and Bereavement
Nutrition and Cancer
Sexuality & Fertility
Side Effects
Support
Survivorship
Exercise and Cancer
Cancer Resources
Cancer News
OncoLink University
Nurses' Notes
Conferences
Newly Diagnosed Patients
Causes and Prevention
Legal and Financial Information for Patients
LGBT Resources
NCI Resources
Global Resources
Cancer Resource List
Resources for Young Adults
OncoLink Media Library
OncoLink TV
Book, Music and Video Reviews
Ask the Experts
Brown Bag Chat
Tracy's Corner
About OncoLink
About OncoLink
Giving to OncoLink
Contact Information
Usage Policy
Editorial Board
How to Partner with OncoLink
Link to OncoLink
Mission Statement
Calcium Leucovorin, Citrovorum Factor, Folinic Acid
Cladribine (2-CDA, Leustatin®)
Cyclophosphamide (Cytoxan®, Neosar®, Endoxan®)
Cyclosporine (Neoral®, Sandimmune®, Restasis®, Gengraf®)
Cytarabine (Cytosar-U®, Ara-C)
Irinotecan (Camptosar®, CPT-11)
Leucovorin (Calcium Leucovorin, Citrovorum Factor, Folinic Acid)
Calcium Leucovorin, Citrovorum Factor, Folinic Acid
Leucovorin (Calcium Leucovorin, Citrovorum Factor, Folinic Acid)
Leuprolide Acetate (Lupron®, Lupron Depot®, Eligard®, Prostap®, Viadur®) - For Men
Leuprolide Acetate (Lupron®, Lupron Depot®, Eligard®, Prostap®, Viadur®) - For Women
Lupron®, Lupron Depot®, Eligard®, Prostap®, Viadur®
Lupron®, Lupron Depot®, Eligard®, Prostap®, Viadur®
Busulfan (Myleran®, Busulfex®)
Intravesicular Mitomycin (Mutamycin®, Mitomycin-C, given into the bladder)
Mechlorethamine (Mustargen®, Nitrogen Mustard)
mechlorethamine, mustine, Mustargen®
Megestrol (Megace®, Megace-ES®)
Mercaptopurine (Purinethol®, 6-MP)
Methotrexate (Mexate®, Folex®, Rheumatrex®, Amethopterin, MTX)
Mexate®, Folex®, Rheumatrex®, Amethopterin, MTX
Mitomycin (Mutamycin®, Mitomycin-C)
Morphine Sulfate (Given by IV)
Morphine Sulfate (MS Contin®, Avinza®, Kadian®, Oramorph SR®)
MS Contin®, Avinza®, Kadian®, Oramorph SR®
Mutamycin®, Mitomycin-C, given into the bladder
Nitrogen mustard (mechlorethamine, mustine, Mustargen®)
Bendamustine Hydrochloride (Treanda®)
Bexarotene (Targretin®), Oral Formulation
Bexarotene Gel (Targretin® Gel Formulation)
Etoposide (Toposar®, VePesid®, Etopophos®,VP-16)
Thioguanine (6-TG, Thioguanine Tabloid®)
Toposar®, VePesid®, Etopophos®,VP-16
Trelstar LA® and Trelstar Depot®
Tretinoin (Vesanoid®, All-Trans-Retinoic Acid, ATRA)
Triptorelin (Trelstar LA® and Trelstar Depot®)

